A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.

Trial Profile

A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs Ruxolitinib (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera; Thrombocytosis
  • Focus Adverse reactions
  • Acronyms PHAZAR
  • Most Recent Events

    • 30 Mar 2015 New source identified and integrated (ISRCTN: Current Controlled Trials: ISRCTN16783472)
    • 17 Mar 2015 Planned End Date changed from 1 Dec 2017 to 4 Jun 2018 according to UK Clinical Research Network.
    • 26 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top